These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17452938)

  • 21. Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Chiang SR; Chuang YC; Tang HJ; Chen CC; Chen CH; Lee NY; Chou CH; Ko WC
    Crit Care Med; 2009 Sep; 37(9):2590-5. PubMed ID: 19623044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
    Güzel CB; Gerçeker AA
    Chemotherapy; 2008; 54(2):147-51. PubMed ID: 18322363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of colistin alone or in combination with rifampicin or meropenem in a carbapenem-resistant bioluminescent Pseudomonas aeruginosa intraperitoneal murine infection model.
    Cai Y; Yang D; Wang J; Wang R
    J Antimicrob Chemother; 2018 Feb; 73(2):456-461. PubMed ID: 29149302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daptomycin and rifampin alone and in combination prevent vascular graft biofilm formation and emergence of antibiotic resistance in a subcutaneous rat pouch model of staphylococcal infection.
    Cirioni O; Mocchegiani F; Ghiselli R; Silvestri C; Gabrielli E; Marchionni E; Orlando F; Nicolini D; Risaliti A; Giacometti A
    Eur J Vasc Endovasc Surg; 2010 Dec; 40(6):817-22. PubMed ID: 20869272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR; Pressler T; Høiby N
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cecropin B enhances betalactams activities in experimental rat models of gram-negative septic shock.
    Ghiselli R; Giacometti A; Cirioni O; Mocchegiani F; Orlando F; D'Amato G; Sisti V; Scalise G; Saba V
    Ann Surg; 2004 Feb; 239(2):251-6. PubMed ID: 14745334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa.
    Linden PK; Kusne S; Coley K; Fontes P; Kramer DJ; Paterson D
    Clin Infect Dis; 2003 Dec; 37(11):e154-60. PubMed ID: 14614688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic efficacy of the polymyxin-like peptide ranalexin in an experimental model of endotoxemia.
    Ghiselli R; Giacometti A; Cirioni O; Orlando F; Mocchegiani F; Pacci AM; Scalise G; Saba V
    J Surg Res; 2001 Oct; 100(2):183-8. PubMed ID: 11592790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat Pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides.
    Cirioni O; Giacometti A; Ghiselli R; Dell'Acqua G; Gov Y; Kamysz W; Lukasiak J; Mocchegiani F; Orlando F; D'Amato G; Balaban N; Saba V; Scalise G
    Circulation; 2003 Aug; 108(6):767-71. PubMed ID: 12885754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of rifampin to ticarcillin-tobramycin combination for the treatment of Pseudomonas aeruginosa infections: assessment in a neutropenic mouse model.
    Zuravleff JJ; Chervenick P; Yu VL; Muder RR; Diven WF
    J Lab Clin Med; 1984 Jun; 103(6):878-85. PubMed ID: 6427375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation of a nosocomial outbreak by alginate-producing pan-antibiotic-resistant Pseudomonas aeruginosa.
    Yakupogullari Y; Otlu B; Dogukan M; Gursoy C; Korkmaz E; Kizirgil A; Ozden M; Durmaz R
    Am J Infect Control; 2008 Dec; 36(10):e13-8. PubMed ID: 19084158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Miyajima Y; Hiramatsu K; Mizukami E; Morinaga R; Ishii H; Shirai R; Kishi K; Tokimatsu I; Saikawa T; Kadota J
    Int J Antimicrob Agents; 2008 Nov; 32(5):437-40. PubMed ID: 18715759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model.
    Cai Y; Fan Y; Wang R; An MM; Liang BB
    J Antimicrob Chemother; 2009 Sep; 64(3):563-6. PubMed ID: 19561148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current therapies for pseudomonas aeruginosa.
    Giamarellou H; Kanellakopoulou K
    Crit Care Clin; 2008 Apr; 24(2):261-78, viii. PubMed ID: 18361945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of intratracheal administration of novispirin G10 on a rat model of mucoid Pseudomonas aeruginosa lung infection.
    Song Z; Wu H; Mygind P; Raventos D; Sonksen C; Kristensen HH; Høiby N
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3868-74. PubMed ID: 16127064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.
    Song JY; Cheong HJ; Lee J; Sung AK; Kim WJ
    Int J Antimicrob Agents; 2009 Jan; 33(1):33-9. PubMed ID: 18835761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats.
    Muto Y; Suzuki K; Iida H; Sakakibara S; Kato E; Itoh F; Kakui N; Ishii H
    Crit Care Med; 2009 May; 37(5):1744-9. PubMed ID: 19325462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of colistin sulfate ophthalmic solution in therapy of pseudomonas ocular infections.
    Lund MH
    Ann Ophthalmol; 1971 Aug; 3(8):855-8. PubMed ID: 5005928
    [No Abstract]   [Full Text] [Related]  

  • 39. Tachyplesin III and granulocyte-colony stimulating factor enhance the efficacy of tazobactam/piperacillin in a neutropenic mouse model of polymicrobial peritonitis.
    Cirioni O; Ghiselli R; Kamysz W; Orlando F; Silvestri C; Mocchegiani F; Di Matteo F; Kamysz E; Riva A; Rocchi M; Saba V; Scalise G; Giacometti A
    Peptides; 2008 Jan; 29(1):31-8. PubMed ID: 18068869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
    Bergen PJ; Li J; Nation RL; Turnidge JD; Coulthard K; Milne RW
    J Antimicrob Chemother; 2008 Mar; 61(3):636-42. PubMed ID: 18227094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.